The course of chronic myeloid leukemia (CML) has changed substantially thanks to the use of a class of drugs called tyrosine kinase inhibitors (TKIs). How these drugs are being used is changing too.

Leukemia is a disease of the blood cells. Acute myeloid leukemia (AML) is seen as an explosion of cancer cells in the bone marrow.

The link between cancer and the body's metabolism is a scientific focus that is bearing more fruit. An " oncometabolite " is cancer-causing metabolite that's involved in the development and progression of cancer.

With all the differences that can occur on a molecular level between one person and another, it shouldn't be surprising that a medication may not work as well for everyone. 

Screenwriter and filmmaker, Nora Ephron , has died after battling leukemia. She was 71.

Drug resistance remains a significant problem in cancer treatment. The contrast of smashing success early on makes any treatment failure later on even more baffling.

The legacy of childhood cancer, in addition to never being quite sure if the cancer is gone for good, also includes the literal scars from treatment.

A number of common chemotherapy agents, such as cisplatin , contain the element platinum. And while effective against cancer cells, these medications can damage healthy cells.

The introduction of Gleevec  in 2001 to treat chronic myeloid leukemia ( CML ) marked one of modern oncology's biggest success stories. The treatment has become the model for other cancer drugs.

Once a resistance to chemotherapy develops in leukemia, it can be extremely difficult to turn back the tide. A new drug focuses on changing that.